-
Dtsch Arztebl Int: Increased risk of skin tumors and infectious diseases after organ transplantation?
Time of Update: 2022-01-23
In a retrospective study published today in Dtsch Arztebl Int, researchers selectively reviewed publications obtained through a PubMed search discussing the incidence and major risk factors of skin tumors and skin infections in immunosuppressed patients .
-
BJU Int: Clinicopathological predictors of inguinal lymph node metastasis in penile cancer patients
Time of Update: 2022-01-23
Calibration plot of the final model Calibration plot of the final modelIn conclusion, there is a small subset of clinically significant inguinal pelvises with additional LNM after completion of ILND in DSNB-positive patients .
After completion of ILND in DSNB-positive patients, there was a small subset of clinically significant inguinal pelvis with additional LNM present .
-
Thorac Cancer: Retrospective analysis of factors associated with long-term survival in NSCLC patients treated with nivolumab
Time of Update: 2022-01-23
Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab.
-
Radiology: Tumor-wide histogram analysis of multiple spread markers for glioma genotyping
Time of Update: 2022-01-23
05) and 1p/19q coding deletions in gliomas with IDH mutations in DTI, DKI, NODDI, MAP, and total diffusion models There were no significant differences in the area under the receiver operating characteristic curve (AUC, 0.
-
BMC Cancer: Prospective study with up to 10 years of follow-up confirms that younger women with non-metastatic breast cancer have worse prognosis
Time of Update: 2022-01-23
In conclusion, this prospective study confirms that young age (<40 years) is a poor prognostic factor in patients with non-metastatic breast cancer .
In conclusion, this prospective study confirms that young age (<40 years) is a poor prognostic factor in patients with non-metastatic breast cancer .
-
European Radiology: Lung-RADS classification application of computer-aided diagnosis in CT screening of lung cancer
Time of Update: 2022-01-23
diagnosisRecently, a study published in the journal European Radiology evaluated the impact of CAD on inter-reader consistency in pulmonary RADS classification, providing a guarantee for the automatic detection and risk assessment of pulmonary nodules, and improving the consistency of image interpretation.
-
European Radiology: How to predict early temporal lobe injury after radiotherapy for nasopharyngeal carcinoma?
Time of Update: 2022-01-23
This study constructs and validates an MRI-based radiomics nomogram that combines radiomics features and clinical factors and can be used to predict RTLI in patients with nasopharyngeal carcinoma .
-
Eur J Cancer: Palbociclib or placebo combined with fulvestrant in patients with HR+/HER2- advanced breast cancer
Time of Update: 2022-01-23
Efficacy assessmentEfficacy assessmentIn subgroup analysis, among patients with visceral metastases, the median PFS in the fulvestrant + palbociclib group and fulvestrant + placebo group was 30.
In subgroup analysis, among patients with visceral metastases, the median PFS in the fulvestrant + palbociclib group and fulvestrant + placebo group was 30.
-
J Clin Oncol: Ibrutinib (ibrutinib) combined with Rituximab (rituximab) in the treatment of indolent mantle cell lymphoma (IMCL-2015)
Time of Update: 2022-01-23
Recently, the Journal of Clinical Oncology published the results of a phase II study IMCL-2015 from Spain , which mainly evaluated the use of Ibrutinib (ibrutinib) in combination with Rituximab in patients with clinically indolent mantle cell lymphoma (MCL).
-
J Clin Oncol: Phase III clinical study evaluating the efficacy of PD-1 inhibitor Spartalizumab combined with Dabrafenib (dabrafenib) + Trametinib (trametinib) in the treatment of BRAF V600-mutated unresectable or metastatic melanoma
Time of Update: 2022-01-23
The 24-month progression-free survival rates were 44% (95% CI, 37 - 50) and 36% (95% CI, 30 - 42) in the two groups, respectively .
The 24-month progression-free survival rates were 44% (95% CI, 37 - 50) and 36% (95% CI, 30 - 42) in the two groups, respectively .
-
Super easy!
Time of Update: 2022-01-23
Cancer was estimated to kill 9. 6 million people in 2018, the second leading cause of death globally, after cardiovascular disease . The economic burden of cancer on patients and healthcare systems
-
BMC Cancer: Propensity Score Matching (PSM) Study Shows Anti-PD-1 Combined with Sorafenib Improves Outcomes in Patients with Advanced Hepatocellular Carcinoma Compared with Anti-PD-1 Monotherapy
Time of Update: 2022-01-23
In conclusion, this study shows for the first time that anti-PD-1 combined with sorafenib improves the prognosis of patients with advanced hepatocellular carcinoma compared with anti-PD-1 monotherapy .
-
Have you seen tumor cells in ascites routine?
Time of Update: 2022-01-23
forewordforewordRoutine specimens of the serous cavity can be accessed by the laboratory almost every day. The routine examination of these specimens not only includes routine physical examinations,
-
Cancers: Real-world study shows that adding bevacizumab to afatinib does not significantly improve outcomes in patients with EGFR-sensitive NSCLC
Time of Update: 2022-01-23
Lung cancerNSCLCA total of 405 patients with advanced NSCLC with sensitizing EGFR mutations received first-line afatinib alone or in combination with bevacizumab and were group- and propensity-score-matched .
-
JAHA: 'Viagra' found to have potentially deadly side effects, promote worsening abdominal aneurysm
Time of Update: 2022-01-23
from the University of Rochester, USA, published a research paper titled: Sildenafil (Viagra) Aggravates the Development of Experimental Abdominal Aortic Aneurysm in the Journal of the American Heart Association (JAHA) .
-
BMC Cancer: Nab-paclitaxel combined with PD-1 inhibitor sintilimab is a promising treatment for advanced soft tissue sarcoma (STS)
Time of Update: 2022-01-23
Therefore, a team from Henan Cancer Hospital conducted a retrospective study to evaluate the efficacy of albumin-paclitaxel combined with PD-1 inhibitor sintilimab in the treatment of patients with advanced soft tissue sarcoma (STS) .
-
Gastrointest Endosc: Long-term survival after endoscopic resection in elderly patients with early gastric cancer
Time of Update: 2022-01-23
The researchers recruited patients with early gastric cancer ≥ 75 years old who were treated with ER from 4 medical institutions from January 2007 to December 2012, and collected clinical data of the patients undergoing endoscopic resection, including the ECOG table.
-
European Radiology: Evaluation of FROC model and two-parameter VI-RADS for staging and grading of bladder urothelial carcinoma
Time of Update: 2022-01-23
diagnosisRecently, a study published in the journal European Radiology explored the feasibility of staging and grading urothelial carcinoma using DWI and FROC models at high b-values, compared the performance of FROC parameters with ADCs, and investigated The improved diagnostic performance of FROC parameters when combined with a simplified version of VI-RADS provides strong support for noninvasive and accurate preoperative assessment of bladder cancer .
-
JCO: Professor Qiang Li found that a PRO-based active management model can reduce the symptom burden and complications of lung cancer patients after discharge
Time of Update: 2022-01-23
This study is the first in the world to verify that the PRO-based active symptom monitoring-warning-feedback whole-process management model can accelerate the postoperative recovery of lung cancer patients, and the patient satisfaction is high; for the first time in the Chinese cultural background and medical system, it is proved that the PRO-based initiative The management model is effective and feasible in the surgical field, which is beneficial to clinical promotion .
-
Thorac Cancer: Chemotherapy combined with immunotherapy after progression on osimertinib for advanced NSCLC is superior to chemotherapy alone
Time of Update: 2022-01-23
The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety of patients in groups IO+C and C were evaluated .
